Skip to content
  • Facebook
  • Twitter
This translation is automatically provided by Google; please refer to the original English version for appropriate wording.
Take on Typhoid

Take on Typhoid

  • Home
  • Why Typhoid?
    • Typhoid & Related Salmonelloses
    • Global Research
    • Links & Resources
  • The Issues
    • Vaccines
    • WASH
    • Drug-Resistant Typhoid
    • Treatment
    • Diagnostics
    • Typhoid intestinal perforation
    • Related Issues
  • Resources & Tools
    • Talk About Typhoid
    • Global Policy
    • Country Tools
    • Infographics
    • Fact Sheets
    • TCV Cost-effectiveness
    • Share on Social
  • Blog & News
    • Blog
    • News
    • Publications
    • Newsletter
  • International Conference
    • Call for Abstracts
    • Travel Awards
    • SeroCalculator Workshop
    • Past Conferences
  • About Us
    • About the Coalition against Typhoid
    • About the Typhoid Vaccine Acceleration Consortium

Typhoid vaccine Phase 3 trial in Nepal

Posted on January 3, 2020 by admin
  • In Nepal, the typhoid conjugate vaccine has proven to be very effective in protecting against typhoid fever
  • The typhoid antibody titers more than quadrupled in the participants that received the typhoid conjugate vaccine

Post navigation

Daewoong launches oral typhoid fever vaccine
13 suspected typhoid cases hit Glen View

Newsletter Signup

Recent Posts

  • Act now to stop drug resistance and prevent typhoid

  • More vaccines, more protection: Promising results for new typhoid conjugate vaccine

  • Quelles leçons tirer d’un cas de fièvre typhoïde à propos de la résistance aux médicaments et des complications graves de la maladie

  • Strengthening typhoid surveillance and immunization in Fiji

  • What one typhoid case tells us about drug resistance and severe typhoid complications

cat
685 West Baltimore Street, Room 480
Baltimore, MD 21201-1509
Coalition against Typhoid
2000 Pennsylvania Ave, NW, Suite 7000
Washington, DC 20006
© 2018. Coalition Against Typhoid. All Rights Reserved.
  • Contact Us
  • Privacy Policy
  • Facebook
  • Twitter
Top